Clinical Trials
11 trialsNCT03392246 2026-05-27
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT03581487 2025-11-05
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT02503358 2023-03-21
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01146756 2023-02-15
MEKRT
The Christie NHS Foundation Trust
Phase 1 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT02450656 2018-08-27
M14AFS
The Netherlands Cancer Institute
Phase 1/2 Unknown
NCT02025114 2018-07-10
Selumetinib in Combination With Gefitinib in NSCLC Patients
National Taiwan University Hospital
Phase 1/2 Completed
NCT03004105 2018-03-16
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn